Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I DDI Study of Garsorasib in Healthy Males
NCT06105255Phase 1Completed
- Sponsor
- InventisBio
- Start
- May 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of garsorasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC) and 1 more (3 arms), sponsored by InventisBio. Primary endpoints: Maximum Concentration at Day 10, Area Under the Concentration-Time Curve from time 0 to time t at Day 10 and 4 more. Started May 2023; status: completed.
02
Drugs
garsorasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT06105255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06105255.